Symposium:
128. Late Breaker II
Friday, October 6, 2017: 10:30 AM-12:00 PM
Room: 06CF

Learning Objectives:

At the conclusion of this sessions, participants will be able to:

  • describe the impact of the opioid crisis on infectious diseases and various healthcare entities response
  • discuss the outbreak of Cholera in Yemen as well as current issues surrounding the vaccine
  • summarize the epidemiology of the yellow fever outbreak in Brazil as well as current research on the virus

Target Audience: Academicians, Clinicians, Epidemiologists, Fellows, Healthcare workers, HIV clinicians, HIV specialists, Hospital administrators, Hospital epidemiologists, Infection preventionists, Infectious diseases pediatricians, Infectious diseases physicians, Investigators, Lab personnel, Medical students and residents, Members-in-training, Microbiologists, Nurses, Pharmacists, Public health practitioners, Researchers, Scientists, Vaccinologists

Tracks: Pediatric ID, Global ID, Adult ID


Moderator:  David R. Andes, M.D., FIDSA, University of Wisconsin School of Medicine and Public Health

Presentations:
10:30 AM
971
Opioid Crisis
Susana Keeshin, MD
10:55 AM
972
Yellow Fever and Vaccine Shortages
Daniel Lucey, MD, MPH

11:45 AM
Q&A

CME Credits: Maximum of 1.50 hours of AMA PRA Category 1 Credit™

ACPE Number: 0221-9999-17-382-L01-P

Disclosures:

D. R. Andes, Medicines: Consultant , Consulting fee
Zavante: Consultant and Grant Investigator , Consulting fee and Grant recipient
Paratek: Research Contractor , Research grant
Actelion: Grant Investigator , Grant recipient
Amplyx: Grant Investigator , Grant recipient
Geom: Grant Investigator , Grant recipient
Meiji: Grant Investigator , Grant recipient
Cidaria: Grant Investigator , Grant recipient
Theravance: Consultant and Grant Investigator , Consulting fee and Grant recipient
Astellas: Grant Investigator , Grant recipient

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.